Cardiac Myosin Inhibitors in HCM Hypertrophic cardiomyopathy (HCM) is a genetic and myocardial disorder characterized by left ventricular hypertrophy and complex phenotypic heterogeneity. Conventional pharmacological therapies, including beta-blockers, calcium channel blockers, and disopyramide, mainly improve the symptoms of HCM. However, a new class of therapies, cardiac myosin inhibitors, are disease-specific and target left ventricular hypercontractility.
“Cholesterol-years” for ASCVD Risk Prediction and Treatment Low-density lipoprotein cholesterol (LDL-C) exposure is associated with atherosclerotic cardiovascular disease (ASCVD) development and the severity of the disease. Recent studies have demonstrated that elevated levels of LDL-C in the early stage of life (18 to 30 years) increase the long-term risk of a future cardiovascular event. In addition, initiating treatment to…
